Thus, our results in clinical samples and preclinical models suggest the initiation of clinical studies of (neo)adjuvant TIM3 blockade for TIM3+ stage-II/III high-risk breast cancer patients to halt subclinical metastasis. Here, HAVCR2 is linked to breast carcinoma.